莫西沙星与哌拉西林舒巴坦钠治疗社区获得性肺炎的比较研究

Comparative Study of Moxifloxacin and Piperacillin Sulbactam Sodium in Treatment of Community Acquired Pneumonia

目的比较莫西沙星与哌拉西林舒巴坦钠治疗社区获得性肺炎的临床疗效。方法 2010年3月-2011年3月,98例社区获得性肺炎患者随机分为两组,A组49例采用莫西沙星治疗,B组49例采用哌拉西林舒巴坦钠治疗,比较观察两组的临床疗效以及主要症状、体征恢复情况。结果 A组的总有效率和细菌清除率明显高于B组(P<0.05)。A组咳嗽消失、体温恢复正常、血常规恢复正常和胸部影像明显吸收时间明显短于B组(P<0.05)。结论与哌拉西林舒巴坦钠比较,莫西沙星对社区获得性肺炎进行治疗,疗效显著,并且患者症状、体征恢复较快,是治疗获得性肺炎的良好选择。

Objective To compare the clinical efficacy of moxifloxacin and piperacillin sulbactam sodium in the treatment of community acquired pneumonia. Methods Ninety- eight patients with community acquired pneumonia hospitalized in the 264 Hospital of Chinese PLA from March 2010 to March 2011 were randomly divided group A and group B （each n = 49）. Group A was treated with moxifloxacin, while group B was received piperacillin sulbactam sodium. The effective rate, the main clinical symptoms and physical signs were compared between the two groups. Results The total effective rate and bacterial clearance rate in group A were significantly higher than those in group B （P 〈 0.05）. The time of cough disappearance, the duration of re- turning to normal body temperature, returning to normal blood, and obvious absorption of pnetmaonic loci in group A were significantly shorter than those in group 13 （P〈 0.05 ）. Conclusions Compared with piperacillin sulbactam sodium, moxifloxacin has the advantages of good therapeutic effects and rapid recovery of the patients in the treatment of community acquired pneumonia. It is a good choice for community acquired pneumonia.